Tag Archive for: liver cirrhosis

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

/in

Edinburgh and London, UK, 10 December 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy (“RMT”) in inflammatory and fibrotic diseases,  today announces it has presented a poster at the Keystone Symposia Fibrosis: Inflammation, Drivers, and Therapeutic Resolution taking place on 8 – 11 December 2024 in […]

Read more

Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain

/in

EMERALD Study will investigate the safety and efficacy of RTX001, an engineered macrophage cell therapy, in patients with end-stage liver disease Recruitment already underway in the U.K., following recent MHRA approval Edinburgh and London, UK, 19 November 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies in inflammatory and fibrotic […]

Read more

Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD The Liver Meeting® 2024 to Support the Ongoing Phase 1/2 Study for RTX001 in End-Stage Liver Disease.

/in

– Complete 3-year clinical data from the MATCH Phase 2 study demonstrate long-term efficacy and safety with autologous, non-engineered macrophages in patients with advanced liver cirrhosis. – New preclinical data support superior anti-inflammatory and anti-fibrotic effect of RTX001, an engineered macrophage investigational therapy, compared to non-engineered macrophages. – RTX001 has recently entered into a Phase […]

Read more

Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment

/in

Financing to advance lead asset RTX001, an engineered, pro-regenerative macrophage therapy with first-in-class potential for end-stage liver disease, into the Phase I/II EMERALD study Proceeds also strengthen manufacturing capabilities and support macrophage therapy pipeline growth in inflammatory and fibrotic indications beyond liver disease Paul Sekhri, seasoned life sciences executive with decades of drug development and […]

Read more

Resolution Therapeutics Announces Upcoming Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024

/in

– Oral Presentation of complete data from the three-year MATCH Phase 2 trial – Poster Presentation demonstrating preclinical proof of concept of safety and efficacy of RTX001, an autologous engineered macrophage cell therapy for end stage liver disease Edinburgh and London, UK, 1 October 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company […]

Read more